- Why in news
- On 27-28 February 2026, the Indian Pharmacopoeia Commission and AMTZ held the first national annual meet of PvPI and MvPI regional centres at Visakhapatnam. The ADR PvPI 2.0 mobile app was launched at the meet.
- What it is
- The Indian Pharmacopoeia Commission (IPC) is an autonomous body under the Union Health Ministry. It sets drug quality standards through the Indian Pharmacopoeia. It also runs the Pharmacovigilance Programme of India (PvPI) and the Materiovigilance Programme of India (MvPI), which track adverse drug reactions and medical device events.
- Meet
- The meet was the first national annual meeting of PvPI and MvPI regional centres, held at AMTZ, Visakhapatnam.
- New app
- The ADR PvPI 2.0 Mobile Application was launched to ease reporting of adverse drug reactions and capture data in real time.
- Key problems
- Technical sessions flagged underreporting of adverse drug reactions, documentation gaps and weak medical device safety oversight.
- Parent ministry
- IPC works under the Ministry of Health and Family Welfare. Its Secretary-cum-Scientific Director presided over the inaugural session.
- Main work
- IPC publishes the Indian Pharmacopoeia, the official book of drug standards in India under the Drugs and Cosmetics Act, 1940.
- Legal basis
- IP is published by the IPC on behalf of the Health Ministry to meet the requirements of the Drugs and Cosmetics Act 1940. Its standards are legally enforceable.
- Blood component monographs
- IP 2026 includes 20 blood component monographs for transfusion medicine for the first time, under the Drugs and Cosmetics (Second Amendment) Rules, 2020.
- PvPI ranking
- India was ranked 123rd in contributions to the WHO pharmacovigilance database in 2009-2014. It rose to 8th in 2025.
Don’t confuse with Pharmacovigilance vs materiovigilance: Pharmacovigilance tracks adverse reactions to drugs (PvPI, via ADR Monitoring Centres). Materiovigilance tracks adverse events from medical devices (MvPI, via Medical Device Monitoring Centres).
Don’t confuse with Pharmacopoeia vs Pharmacovigilance: The Pharmacopoeia sets quality standards for drugs. Pharmacovigilance tracks adverse drug reactions after drugs are in use. The IPC does both through IP and PvPI.
Don’t confuse with IPC vs CDSCO: The IPC sets drug standards. The CDSCO, headed by the Drugs Controller General (India), regulates approval and licensing of drugs.
Laws, judgments and statutory bodies: 30 Prelims questions since 2013 (what the law says, who chairs, legal basis). In Mains, 44 news-triggered questions, most in GS2, asking for provisions and challenges.
Why it matters
- Systematic reporting of adverse events helps detect unsafe drugs and devices early and protects patients.
- Legally enforceable standards help assure the quality and safety of medicines used under national health programmes.
- Global recognition and harmonisation support India's role in the pharmaceutical supply chain and health diplomacy.
Problems
- Underreporting of adverse drug reactions and gaps in documentation weaken the data.
- Device safety oversight is still thin, and reach below district-level facilities is limited.
- Standards help only if state regulators enforce them and test samples; spurious and substandard drugs persist.
- Adverse reaction reporting depends on clinicians, patients and pharmacists, and under-reporting is common.
Way forward
- Build capacity, standardise reporting and use technology tools such as the mobile app to widen reporting.
- Improve coordination among regulators, hospitals and monitoring centres, and extend outreach beyond district facilities.
- Strengthen state drug-testing capacity and enforcement of IP standards.
- Widen awareness and reporting of adverse drug reactions to keep improving pharmacovigilance.
Put in your answer
ADR PvPI 2.0 app: Example of technology-enabled patient safety reporting, aimed at real-time data capture.
IP 2026 coverage: The new edition strengthens monographs on anti-TB, anti-diabetic and anti-cancer medicines and iron supplements, which are used in national health programmes.
PvPI progress: India's rise from 123rd to 8th in WHO pharmacovigilance contributions shows the effect of a strengthened reporting system.
- 2015Mains GS2 · Q16Discuss whether regulatory institutions must remain independent and autonomous, using recent experience
- 2013Mains GS3 · Q14Define fixed dose combinations; discuss merits and demerits.
- 2014Mains GS3 · Q11Overuse of antibiotics causing drug resistance; available monitoring and control mechanisms.
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
No practice question for this one; the card may still help an answer. Why: Lasting drug-safety bodies; first national meet and a mobile app launched. UPSC rarely asks about such bodies (statutory bodies 7 of 327 Prelims).
Worth revising until Prelims 2027: most news questions come within two years of the event.